SPRIX (ketorolac tromethamine) by Fresenius Kabi is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. First approved in 2010.
Drug data last refreshed 16h ago · AI intelligence enriched 19h ago
SPRIX is a nasal spray formulation of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) that provides rapid analgesic activity through prostaglandin synthetase inhibition. It is indicated for short-term management of moderate to severe acute pain in adults. The S-enantiomer of ketorolac is responsible for analgesic activity, with peak effects occurring within 2-3 hours.
SPRIX faces approaching loss of exclusivity with modest Medicare utilization (779 claims, $2M spend in 2023), indicating a niche product with limited team expansion opportunities.
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on SPRIX at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment
Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment
Safety and Efficacy of Olopatadine Hydrochloride/Ketorolac Tromethamine Ophthalmic Solution Compared With Olopatadine Hydrochloride Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis
A 6 Month Study to Evaluate the Safety, Analgesic Efficacy of ACUVAIL™ (Ketorolac Tromethamine Ophthalmic Solution) 0.45%, in Post-PRK Corneal Wound Healing
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moSPRIX offers limited career growth opportunities given its approaching loss of exclusivity and minimal current market penetration (779 Medicare claims). Roles focused on brand management, market access, and regulatory compliance may be available, but the trajectory points toward portfolio consolidation rather than expansion.